Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...
Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to a U.S. regulatory decision ...
Ianalumab, a monoclonal antibody, helped patients with immune thrombocytopenia (ITP) maintain safe platelet counts without ...
6d
Charlie Sheen claims experimental HIV drug was kept off market because 'it's a threat' to industry
Charlie Sheen reveals an experimental HIV drug that "never made it to market" and discusses his sobriety journey since 2017 ...
An experimental pain-relieving drug delivery method for farm animals using microneedle patches may not have delivered an ...
Adagene (ADAG) stock and Palvella Therapeutics (PVLA) stock rise as the FDA issued Fast Track Designations for the companies' ...
Physicians stand to earn big money when signing up patients for drug trials. And lately, some of those trials have been ...
French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...
Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...
Dec 12 () - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...
Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor. The oral drug, varegacestat, is being tested in patients with desmoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback